Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis.

Berical A, Lee RE, Randell SH, Hawkins F.

Front Pharmacol. 2019 Feb 8;10:74. doi: 10.3389/fphar.2019.00074. eCollection 2019. Review.

2.

A functional macrophage migration inhibitory factor promoter polymorphism is associated with reduced diffusing capacity.

Zhang C, Ramsey C, Berical A, Yu L, Leng L, McGinnis KA, Song Y, Michael H, McCormack MC, Allore H, Morris A, Crothers K, Bucala R, Lee PJ, Sauler M.

Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L400-L405. doi: 10.1152/ajplung.00439.2018. Epub 2018 Dec 6.

PMID:
30520689
3.

Pulmonology in Pregnancy.

Abston ED, Hon SM, Berical A.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):127-129. doi: 10.1164/rccm.201707-1436RR. No abstract available.

PMID:
29155600
4.

Pneumococcal Vaccination Strategies. An Update and Perspective.

Berical AC, Harris D, Dela Cruz CS, Possick JD.

Ann Am Thorac Soc. 2016 Jun;13(6):933-44. doi: 10.1513/AnnalsATS.201511-778FR. Review.

5.

Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility.

Ansari IU, Allen T, Berical A, Stock PG, Barin B, Striker R.

Virology. 2013 Feb 20;436(2):268-73. doi: 10.1016/j.virol.2012.11.018. Epub 2013 Jan 2.

6.

Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.

Newman RM, Kuntzen T, Weiner B, Berical A, Charlebois P, Kuiken C, Murphy DG, Simmonds P, Bennett P, Lennon NJ, Birren BW, Zody MC, Allen TM, Henn MR.

J Infect Dis. 2013 Jul;208(1):17-31. doi: 10.1093/infdis/jis679. Epub 2012 Nov 6.

7.

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.

Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM.

PLoS Pathog. 2012;8(3):e1002529. doi: 10.1371/journal.ppat.1002529. Epub 2012 Mar 8.

8.

Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase.

Oniangue-Ndza C, Kuntzen T, Kemper M, Berical A, Wang YE, Neumann-Haefelin C, Foote PK, Hills-Evans K, Reyor LL, Kane K, Gladden AD, Bloom AK, Power KA, Thimme R, Lauer GM, Henn MR, Kim AY, Allen TM.

J Virol. 2011 Nov;85(22):11883-90. doi: 10.1128/JVI.00779-11. Epub 2011 Aug 31.

9.

Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase.

Peng LF, Schaefer EA, Maloof N, Skaff A, Berical A, Belon CA, Heck JA, Lin W, Frick DN, Allen TM, Miziorko HM, Schreiber SL, Chung RT.

J Infect Dis. 2011 Aug 15;204(4):609-16. doi: 10.1093/infdis/jir303.

10.

Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.

Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM.

Gastroenterology. 2011 Feb;140(2):686-696.e1. doi: 10.1053/j.gastro.2010.09.042. Epub 2010 Sep 24.

11.

Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution.

Kasprowicz V, Kang YH, Lucas M, Schulze zur Wiesch J, Kuntzen T, Fleming V, Nolan BE, Longworth S, Berical A, Bengsch B, Thimme R, Lewis-Ximenez L, Allen TM, Kim AY, Klenerman P, Lauer GM.

J Virol. 2010 Feb;84(3):1656-63. doi: 10.1128/JVI.01499-09. Epub 2009 Nov 11. Erratum in: J Virol. 2011 May;85(9):4636.

12.

Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.

Kim AY, Timm J, Nolan BE, Reyor LL, Kane K, Berical AC, Zachary KC, Lauer GM, Kuntzen T, Allen TM.

J Infect Dis. 2009 Mar 1;199(5):737-41. doi: 10.1086/596657.

13.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.

Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM.

Hepatology. 2008 Dec;48(6):1769-78. doi: 10.1002/hep.22549.

14.

A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame.

Kuntzen T, Berical A, Ndjomou J, Bennett P, Schneidewind A, Lennon N, Birren BW, Kuiken C, Henn MR, Simmonds P, Allen TM.

J Med Virol. 2008 Aug;80(8):1370-8. doi: 10.1002/jmv.21240.

15.

High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome.

Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan BE, Longworth S, Berical A, Blum J, McMahon C, Reyor LL, Elias N, Kwok WW, McGovern BG, Freeman G, Chung RT, Klenerman P, Lewis-Ximenez L, Walker BD, Allen TM, Kim AY, Lauer GM.

J Virol. 2008 Mar;82(6):3154-60. Epub 2007 Dec 26. Erratum in: J Virol. 2011 May;85(9):4633.

16.

Viral sequence evolution in acute hepatitis C virus infection.

Kuntzen T, Timm J, Berical A, Lewis-Ximenez LL, Jones A, Nolan B, Schulze zur Wiesch J, Li B, Schneidewind A, Kim AY, Chung RT, Lauer GM, Allen TM.

J Virol. 2007 Nov;81(21):11658-68. Epub 2007 Aug 15.

17.

Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Schulze Zur Wiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, Jones AM, Nolan BE, Longworth SA, Kasprowicz V, McMahon C, Wurcel A, Lohse AW, Lewis-Ximenez LL, Chung RT, Kim AY, Allen TM, Walker BD.

Blood. 2007 Sep 1;110(5):1559-69. Epub 2007 May 2.

Supplemental Content

Loading ...
Support Center